Osteosarcoma is characterized by frequent relapse and metastatic disease associated with resistance to chemotherapy. We previously showed that syndecan-2 is a mediator of the antioncogenic effect of chemotherapeutic drugs. The purpose of this work was to elucidate molecular mechanisms responsible for the low expression of syndecan-2 in osteosarcoma. We compared the regulatory activity of cis-acting DNA sequences of the syndecan-2 gene in osteosarcoma and osteoblastic cell lines. We identified a DNA region that negatively regulates syndecan-2 transcription in the osteosarcoma cells. T-cell factors (TCF) bind to this sequence in vivo. Wnt3a stimulation, β-catenin activation, and TCF overexpression resulted in syndecan-2 repression, whereas Wnt inhibition using sFRP-1 increased syndecan-2 expression in U2OS cells. RhoA activation blunted the stimulatory effect of sFRP-1 on syndecan-2 transcription, whereas RhoA inhibition enhanced syndecan-2 expression. These results indicate that Wnt/β-catenin and Wnt/RhoA signaling contribute to syndecan-2 repression. The alteration of syndecan-2 expression in osteosarcoma cell lines also seemed to be related to a higher shedding, controlled by Wnt/RhoA. Conversely, syndecan-2 was found to activate its own expression in U2OS cells through RhoA inhibition. These data identify a molecular network that may contribute to the low expression of the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. The high activity of the canonical Wnt pathway in the different osteosarcoma cells induces a constitutive repression of syndecan-2 transcription, whereas Wnt/RhoA signaling blocks the amplification loop of syndecan-2 expression. Our results identify syndecan-2 as a Wnt target and bring new insights into a possible pathologic role of Wnt signaling in osteosarcoma. Cancer Res; 70(13); 5399-408. ©2010 AACR.
Introduction
Osteosarcoma is the most common primary bone tumor. In the past decades, multiagent chemotherapy resulted in an improvement in patient survival rates, with up to 70% survival in patients with localized disease. However, osteosarcoma is still characterized by frequent relapse and metastatic disease, which are associated with strong resistance to chemotherapy and therefore poor prognosis (1, 2) . Multiple cellular modifications allow osteosarcoma cells to become resistant to cytotoxic agents (3) . In particular, genetic modifications lead to alterations of key signaling pathways. Notably, Wnt signaling that controls normal bone formation through coordination of proliferation, differentiation, and prevention of apoptosis in osteoblastic cells was shown to be involved in the pathogenesis of osteosarcoma (4) (5) (6) (7) . However, the molecular targets of Wnt signaling in osteosarcoma cells are largely unknown.
It is well established that the action of cytotoxic drugs depends on the induction of apoptosis. Thus, alterations of mechanisms that control cell death contribute to resistance to chemotherapy. Syndecan-2, a membrane heparan sulfate proteoglycan, was shown to modulate events related to the apoptotic response, such as Fas distribution into lipid rafts in fibroblasts (8, 9) . We have previously shown that syndecan-2 controls the induction of apoptosis in osteoblasts, modulating mitogen-activated protein kinase and protein kinase Cδ signaling (10, 11) . Consistently, we showed that syndecan-2 mediates the antioncogenic effects of chemotherapeutic drugs in osteosarcoma cells (12) . Indeed, the level of syndecan-2 determines the ability of osteosarcoma cells to respond to different cytotoxic agents. Although the expression of syndecan-2 in osteosarcoma cell lines and tissues is very low compared with normal osteoblasts and bone tissues, we showed that doxorubicin treatment upregulates syndecan-2 levels in osteosarcoma cells that are sensitive to this drug (12) . Moreover, the levels of syndecan-2 were reported to increase in bone tumors of patients that respond to chemotherapy compared with nonresponder patients (12) . These results led us to postulate that dysregulation of apoptosis in osteosarcoma may be, in part, related to defective syndecan-2 expression and/or induction. Determining the causes of this defect may help to rescue apoptotic signaling in osteosarcoma cells. To determine which factors regulate syndecan-2 expression in osteosarcoma cells, we analyzed the regulatory activity of DNA sequences upstream of the coding region of SDC2 gene in osteosarcoma and osteoblastic cells. We identified T-cell factors (TCF)/lymphoid enhancer factor-1 (LEF-1) as repressors acting downstream of the Wnt/ β-catenin pathway. We also showed that Wnt-dependent RhoA signaling contributes to low syndecan-2 expression in osteosarcoma, regulating the shedding of the proteoglycan from the cell surface. Finally, we report that syndecan-2 can upregulate its own expression through inhibition of RhoA activation. Altogether, this study identifies a molecular network, involving Wnt effectors, which contributes to low syndecan-2 expression.
Materials and Methods

Cell culture and treatments
Human MG63, U2OS, and SaOS2 osteosarcoma cell lines were obtained from the American Type Culture Collection. HOB1 and HOB2 cells are immortalized osteoblastic cells derived from nonpathologic human bone (13, 14) . FHSO cells are clonal fetal human bone marrow stromal preosteoblastic cells (15) . The cells were maintained in DMEM supplemented with 10% FCS and antibiotics (100 IU/mL penicillin and 100 μg/mL streptomycin). Cells were treated with 2.5 μg/mL recombinant human sFRP-1, 0.5 μg/mL recombinant mouse Wnt5a (R&D Systems), or 15% conditioned medium containing recombinant Wnt3a (Wnt3a-CM) that was obtained as previously described (16) .
Transfection and transduction
Cell transfections were performed using the TransFast system (Promega). The following plasmids were used: TOPFlash, TCF-1-pUSEamp (Upstate Biotechnology), mutated β-catenin expression plasmid, β-cateninΔGSK (17), pcDNA3-DKK1 (18), pEGFP-HsRhoA-G14V (pRhoG14V, constitutively active RhoA mutant), and pCMVFLAG-RhoAN19 (pRhoN19, dominant-negative RhoA mutant). The control and specific TCF-4 siRNA are from Santa Cruz Biotechnology. Based on in silico analysis of SDC2 gene, the −3,620-bp sequence located in 5′ of coding sequence in syndecan-2 gene was amplified using bacterial artificial chromosome (clone ID RP11-22I13, accession AC013704) as template. Primers containing HindIII and MluI restriction sites (5′-CCGCTCGAGGAGTCCGATGTGTCAGTTTAGG-3′ and 5′-CGACGCGTGAGTCCGATGTGTCAGTTTAGG-3′) were chosen to include the entire 5′ untranslated region sequence. The PCR products were cloned into the pGL3-BASIC (Promega). The inserts were confirmed by DNA sequencing. To overexpress syndecan-2, cells were transduced with the lentiviral vector TRIP-hSYND, as previously described (12) .
Reverse transcription-PCR analyses
Cells were cultured in triplicate wells in six-well plates. Total RNA was isolated using the Trizol reagent (Invitrogen) and reverse transcribed. Syndecan-2 expression was analyzed by quantitative real-time PCR using SYBR Green, the LightCycler 480 (Roche Molecular Biochemicals), and the following forward and reverse primers: human syndecan-2, 5′-TTGGCTTTCTCTTTGCAATTTT-3′ and 5′-CCTTCATCC  TTCTTTCTCATGC-3′; mouse syndecan-2, 5′-TTCAGGAGTA-TATCCTATTGATGATGA-3′ and 5′-ACTCTCTATGTCTT-CATCAGCTCCT-3′ . Reference genes were glyceraldehyde-3-phosphate dehydrogenase and 18S. Fold changes for transcripts were normalized using the ΔΔC t formula.
Luciferase assay
To test the activity of the different reporter constructs, cells were seeded in 24-well plates and then cotransfected with 0.3 μg/well of TOP-Flash or p-3.62-LUC plasmid, 10 ng/well of phRL-SV40, a Renilla expression plasmid as internal transfection control, and 0.3 μg/well of other expression plasmid or siRNA. Empty pGL3-BASIC served as control for reporter activity. Forty-eight hours after transfection, firefly and Renilla luciferase activities were measured sequentially using Luciferase Reporter Assay System (Promega). Luciferase activity was normalized both to Renilla activity, as transfection control, and to values obtained with cells transfected with an empty pGL3-BASIC, as control of the variations of the phRL-SV40 induced by treatment. Results are expressed as relative luciferase units.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed using the red ChIP kit (Diagenode). Briefly, 10 7 cells were used. DNA and associated proteins were cross-linked with 4% paraformaldehyde, extracted, and incubated overnight at 4°C with rabbit immunoglobulin fraction as a negative control or rabbit polyclonal anti-TCF4 (Santa Cruz Biotechnology) and protein A/G-coated beads. The dissociation of DNA-protein complexes was achieved by heating samples at 65°C. Input and immunoprecipitated chromatin were used for PCR using primers to amplify the −1,995-to −1,563-bp region of 5′ flanking region of syndecan-2 gene (5′-TGGTAGCTGGCACACAAAAC-3′ and 5′-ACAAATCCC TTGCAGTTCGT-3′). The PCR products were separated on 1% agarose gels in the presence of ethidium bromide.
Cell membrane preparation, immunoprecipitation, and Western blot analysis
Cells were lysed on ice in 25 mmol/L HEPES (pH 7.5) buffer containing 150 mmol/L NaCl, 1% Igepal, 10 mmol/L MgCl 2 , 1 mmol/L EDTA, 10% glycerol, and protease inhibitors (MBL buffer). Protein content was determined using the detergent-compatible protein assay (Bio-Rad). The levels of GTP-bound RhoA were measured using the glutathione S-transferase-Rho binding domain protein of Rhotekin (Upstate). To detect RhoA translocated to the membrane, cells were sonicated in 20 mmol/L Tris-HCl (pH 7.2) with 2 mmol/L EDTA, 2 mmol/L EGTA, 0.1% β-mercaptoethanol, and a cocktail of protease inhibitors. The membrane fraction was then separated from the cytosolic fraction by centrifugation at 100,000 × g for 1 hour. Immunoprecipitations were performed by incubating 100 μg of proteins with 2 μg of rabbit anti-p190RhoGAP (Abcam) or control Ig and protein A-coated magnetic beads. Total, membrane, pulled down, or immunoprecipitated proteins were subjected to SDS-PAGE, electrotransferred, and incubated with a rabbit anti-syndecan-2 (Zymed), mouse anti-RhoA (Santa Cruz Biotechnology), mouse anti-phosphotyrosine (PY99; Santa Cruz Biotechnology), or rabbit anti-p190RhoGAP (Abcam) antibodies and then with appropriate horseradish peroxidaseconjugated antibodies. The signals were visualized using a chemiluminescent detection system.
ELISA
The levels of syndecan-2 in the media conditioned on confluent cells or in cellular lysates were quantified using a direct ELISA with rabbit anti-syndecan-2 antibody (Santa Cruz Biotechnology).
Statistical analysis
Every experiment was performed at least three times. Results from one representative experiment are presented. Results are means of at least three values ± SE. Two-tailed Student's t tests were performed for statistical analyses of the results.
Results
Regulation of syndecan-2 transcription in osteoblastic and osteosarcoma cells
To identify the regulators of syndecan-2 expression, we sought to characterize cis-acting sequences in the SDC2 gene. We amplified the −3,620-bp sequence upstream from the ATG codon, cloned the PCR product upstream of the luciferase reporter gene (p-3.62-LUC), and performed restriction digests to test the transcriptional activity of the different chimeric constructs. The full-length sequence promoted luciferase expression (Fig. 1A) . In U2OS osteosarcoma cells, deletion between −3,620 and −974 (p-3.62-KpnI-EcoRI-LUC) or −2,719 to −974 (p-3.62-EcoRI-LUC) resulted in a strong increase in the transcriptional activity, indicating that the p-3.62 sequence comprise negative regulators located between −2,719 and −974 (Fig. 1A) . The transcriptional activity of the 3.62 sequence was higher in osteoblastic cells compared with osteosarcoma cells (Fig. 1B) . Because a deletion between −2,719 to −974 had a smaller effect on the transcriptional activity in osteoblastic cells compared with osteosarcoma cell lines (Fig. 1B) , we postulated that the negative regulators comprised in the sequence may contribute to the low syndecan-2 expression in osteosarcoma cells.
TCFs act as repressors of syndecan-2 expression in osteosarcoma cells downstream of the Wnt canonical pathway
We analyzed the p-3.62 sequence for potential nuclear factor binding sites. Six binding sites for factors of the TCF/LEF family with core similarity scores of 1 and matrix similarity scores ranging from 0.862 to 0.993 were detected. Four of these sites were located between −2,719 and −974. ChIP experiments were performed using U2OS cells using primers to amplify a DNA region spanning two TCF/LEF binding sites in the SCD2 gene or primers to amplify a sequence without TCF binding site. PCR products were obtained using the specific primers and from DNA precipitated with an anti-TCF4 antibody but not with control IgG, indicating that TCFs bind to the DNA sequence in vivo (Fig. 1C) . On the other hand, we found that in the absence of exogenous Wnt stimulation, TOP-Flash activity was constitutively higher in osteosarcoma cells compared with osteoblastic cells (Fig. 1D) , indicative of a high basal transcriptional activity of TCF in U2OS, MG63, and SaOS2 osteosarcoma cells compared with normal osteoblastic cells.
The above results prompted us to investigate the role of the TCFs in syndecan-2 regulation. We used U2OS cells because, given the basal activities, both p3.62-LUC and TCF can be downregulated and upregulated with high sensitivity in these cells. We first increased the level of TCF using an expression plasmid. This resulted in a strong increase in TOP-Flash activity ( Fig. 2A) and in a parallel decrease in p-3.62-LUC activity (Fig. 2B) . TCF overexpression also reduced syndecan-2 mRNA, whereas specific inhibition of TCF expression with siRNA enhanced basal syndecan-2 mRNA levels (Fig. 2C) . These results indicate that TCFs act as repressors of syndecan-2 transcription. TCF overexpression did not modify the activity of the promoter deleted from −2,719 to −974 (Fig. 2B) . We then showed that increasing the levels of active β-catenin also resulted in increased TOP-Flash activity ( Fig. 2A) and decreased p-3.62-LUC activity and syndecan-2 mRNA levels (Fig. 2D) . Coexpression of active β-catenin and TCF in these cells did not further increase TOP-Flash activity or reduce syndecan-2 expression compared with active β-catenin or TCF alone. Treatment with recombinant Wnt3a strongly increased TOP-Flash activity (Fig. 3A) and inhibited both p-3.62-LUC activity and syndecan-2 mRNA (Fig. 3B) . Altogether, these results show that Wnt signaling constitutively represses syndecan-2 expression. Interestingly, the effects of exogenous Wnt3a were reduced when DKK1 was expressed or by cotreatment with sFRP-1 (Fig. 3A-C) . However, DKK1 did not significantly modify either the basal p-3.62-LUC activity or syndecan-2 mRNA levels. In contrast, sFRP-1 strongly enhanced both ( Fig. 3B and C) , suggesting that, besides the β-catenin/TCF pathway, other Wnt-dependent pathways may be involved in syndecan-2 repression.
Noncanonical Wnt pathway involving RhoA contributes to syndecan-2 repression
We then searched for alternative mediators of Wnt signaling that may be involved in syndecan-2 repression in U2OS cells. We hypothesized that RhoA, an antiapoptotic factor in osteosarcoma cells (19) , could be involved in this effect. We therefore counteracted the sFRP-1-induced inhibition of Wnt-dependent RhoA activity using an expression plasmid coding for a constitutively active form of RhoA (pRhoG14V). Activated RhoA abolished the positive effect of sFRP-1 on p-3.62-LUC activity and syndecan-2 RNA expression, but it did not significantly modify the basal level of syndecan-2 RNA and p-3.62-LUC activity (Fig. 4A) . Similarly, exogenous Wnt5a, which is known to signal through RhoA/c-Jun NH 2 -terminal kinase (JNK) pathway (20) , did not modify p-3.62-LUC activity and only weakly decreased syndecan-2 mRNA production in U2OS cells (Fig. 4B) . In contrast, specific inhibition of RhoA by dominant negative (pRhoN19) resulted in a strong enhancement of basal p-3.62-LUC activity and syndecan-2 mRNA expression (Fig. 4C) . Altogether, these results show that RhoA is involved in Wnt-dependent repression of syndecan-2 in U2OS cells.
Syndecan-2 regulates its own expression through inhibition of RhoA signaling
It has previously been reported that syndecans can modulate Wnt signaling (21, 22) . We therefore investigated whether syndecan-2, in turn, may modulate the repressive action of the Wnt factors. Increasing syndecan-2 expression in U2OS cells using a lentiviral vector coding the human gene (TRIP-hSYND2) did not result in a significant change in the basal TOP-Flash activity or the expression of β-catenin, Wnt3a, Wnt5a, or the receptor Ryk1 as evaluated by quantitative PCR (data not shown). These results suggest that syndecan-2 does not influence the Wnt/β-catenin/TCF pathway or the level of Wnt effectors. In contrast, the level of RhoA associated with the membrane or linked to GTP was reduced in U2OS cells transduced with TRIP-SYND2 compared with empty vector, indicating that RhoA activity is reduced in syndecan-2-overexpressing cells (Fig. 5A) . Moreover, the level of activated p190RhoGAP, evaluated by phospho-p190RhoGAP, was higher in syndecan-2-overexpressing cells (Fig. 5A) . We then examined whether syndecan-2 can modulate its own expression by RhoA inhibition. We found that the expression of human syndecan-2 increased endogenous syndecan-2 expression in MC3T3-E1 murine osteoblastic cells (Fig. 5B) . Moreover, increasing the expression of syndecan-2 in U2OS cells significantly enhanced the activity of both full-length and deleted forms of p3.62-LUC, suggesting that syndecan-2 controls its own expression independently of the TCF binding sites (Fig. 5B) . Rescuing RhoA activity in syndecan-2-overexpressing U2OS cells using constitutively active RhoA abolished syndecan-2-induced increase of p-3.62-LUC activity (Fig. 5C) . These results indicate that the inhibition of RhoA activation by syndecan-2 contributes to the upregulation of syndecan-2 expression. Conversely, the positive effect of RhoA inhibition by pRhoN19 on p3.62-LUC activity is reduced when syndecan-2 production is blocked by specific siRNA (Fig. 5D) . This indicates that RhoA may modulate syndecan-2 expression, in part, at the posttranscriptional level. Our results also suggest that an important action of RhoA is to block the amplification loop of syndecan-2 expression.
Wnt signaling regulates syndecan-2 shedding from the cell surface
Syndecan protein levels are known to depend on the shedding of the ectodomain from the cell surface (23) . To determine whether syndecan-2 release is altered in osteosarcoma compared with osteoblastic cells, we examined the levels of the syndecan-2 protein in the culture medium conditioned on the different cell lines using ELISA. Syndecan-2 levels measured in the media were normalized with syndecan-2 levels measured in the corresponding cell lysates. The mean ratio of released syndecan-2 was significantly higher in the medium conditioned on osteosarcoma cell lines compared with osteoblastic cells (Fig. 6A) . Moreover, in U2OS cells, inhibition of Wnt by sFRP-1 reduced syndecan-2 levels in the medium. This effect of sFRP-1 was blunted by the expression of an activated RhoA (Fig. 6B) . pRhoG14V or DKK1 expression did not modify syndecan-2 release (Fig. 6B) . Altogether, these results indicate that Wnt/RhoA signaling is involved in the regulation of syndecan-2 shedding, thereby controlling the self-induction of the proteoglycan in U2OS cells. Figure 2 . TCFs act as repressors of syndecan-2 expression. U2OS cells were transfected with an expression plasmid coding for the human TCF factor and/or activated β-catenin or siRNA targeting human TCF-4. RNAs were extracted 48 h later, reverse transcribed, and used for real-time PCR analysis of syndecan-2 expression. Alternatively, the indicated reporter plasmids were added to the transfection mixtures and luciferase activity was determined. A, effect of TCF overexpression and/or β-catenin activation on TOP-Flash activity. B, effect of TCF overexpression on transcriptional activity of full-length (p-3.62-LUC) or deleted (p-3.62-EcoRI-LUC) cis-regulating DNA of syndecan-2 gene. C, effect of TCF overexpression and TCF suppression on syndecan-2 mRNA expression. D, effect of β-catenin activation and TCF overexpression on the transcriptional activity of the full-length cis-regulating DNA and syndecan-2 RNA levels. *, P < 0.05, significant difference with values obtained at basal conditions.
Discussion
We previously showed that low syndecan-2 expression contributes to defective apoptosis in osteosarcoma and that increasing syndecan-2 levels results in enhanced sensitivity to cytotoxic agents (12) . Thus, the lack of syndecan-2 seems to be a key event in the resistance to DNA-damaging agents that are currently used as chemotherapy for bone tumors and associated metastatic disease. To elucidate the mechanisms responsible for the low expression of syndecan-2 in osteosarcoma cells, we analyzed the regulatory activity of possible cis-acting DNA regions located in the 5′ of the coding sequence of the SDC2 gene. The transcriptional activity of the studied 3,620-bp sequence was consistent with the RNA levels produced in the different cell lines. Indeed, higher basal activity was observed in U2OS compared with MG63 or SaOS2 cells, and more importantly, much higher basal activity was observed in osteoblastic compared with osteosarcoma cell lines, indicating that the choice of this DNA sequence allows for the comparison of the transcriptional regulation of syndecan-2 in osteoblast and osteosarcoma cells. We identified a 1,745-bp region that negatively regulates syndecan-2 transcription in osteosarcoma cells. We have shown the presence of TCF/LEF consensus sites in this sequence, which bind TCF4 in vivo. Deletion of the TCF binding sites from the full-length regulatory sequence abolished the effect of recombinant TCF on luciferase production, indicating a direct action of TCFs on syndecan-2 transcription. We showed that TCFs, as executive factors of the canonical pathway of Wnt signaling, act as repressors of syndecan-2 expression. Interestingly, we found that the lower syndecan-2 expression in osteosarcoma compared with osteoblastic cells is associated with a higher basal TCF-dependent transcription in the absence of exogenous Wnt, β-catenin, or TCF stimulation. These results suggest that increased Wnt/β-catenin/TCF signaling may directly contribute to the low syndecan-2 production in osteosarcoma cells. The idea that TCF-dependent transcription is constitutively activated in osteosarcoma is supported by several studies. For example, epigenetic silencing of Wnt inhibitory factor 1 was reported in bone tumors (24) . Moreover, APC mutations and β-catenin accumulation have been frequently reported in human osteosarcoma (25, 26) . At present, the role of Wnt signaling in tumorigenesis of osteosarcoma is under debate. Altogether, the facts that Wnt signaling is required for osteoblastic differentiation, that DKK1 was shown to block the differentiation and increase the transformation of mesenchymal stem cells, and the reported inactivation of the canonical Wnt pathway in osteosarcoma support the conclusion that silencing of the Wnt/β-catenin signaling contributes to tumorigenesis (27) (28) (29) . In contrast, inhibition of Wnt signaling by a dominant-negative LRP5 was shown to decrease tumorigenicity and metastasis in osteosarcoma in vivo, and Wnt/β-catenin pathway antagonists such as curcumin and PKF118-310 have been shown to have antitumor effects in osteosarcoma cells, indicating a protumoral role of Wnt signaling (30, 31) . Our results, showing an enhanced basal TCF activity in osteosarcoma cells compared with osteoblastic cells and the associated downregulation of the tumor suppressor syndecan-2, strengthen the last hypothesis about the negative role of Wnt signaling in osteosarcoma cells.
Despite the already high basal TOP-Flash activity, we found that exogenous TCF, activated β-catenin, or Wnt3a further stimulated TCF reporter activity and decreased syndecan-2 transcription. Moreover, the Wnt inhibitor DKK1 was still able to inhibit the effect of exogenous Wnt3a but had only a small effect on the basal level of syndecan-2 transcription in an osteosarcoma cell line, whereas sFRP-1 Figure 5 . Syndecan-2 alters RhoA activation and regulates its own expression. A, effect of syndecan-2 overexpression on RhoA activation. Protein extracts were obtained from U2OS cells transduced with the lentiviral vector TRIP-hSYND to overexpress syndecan-2. Rhotekin assays were performed to determine Rho-GTP levels. Membrane fractions were isolated and served to determine RhoA translocated to the membrane. Total protein extracts also served for immunoprecipitation using rabbit anti-p190RhoGAP antibodies and protein A-conjugated magnetic beads. Protein preparations were run on acrylamide gels and electrotransferred to membranes that were blotted with mouse anti-RhoA, rabbit anti-syndecan-2, mouse anti-phosphotyrosine, or anti-p190RhoGAP antibodies. B, effect of syndecan-2 overexpression on syndecan-2 expression. MC3T3-E1 and U2OS cells were transduced with TRIP-hSYND. Total RNA was extracted from MC3T3 cells and served to determine endogenous mouse syndecan-2 expression using quantitative reverse transcription-PCR. U2OS cells were transfected with full-length or deleted syndecan-2 reporter constructs. Relative luciferase activity was determined 48 h later. C, effect of RhoA rescue on p-3.62-LUC activity in syndecan-2-overexpressing cells. U2OS cells transduced with TRIP-hSYND were cotransfected with p-3.62-LUC and control or pRhoG14V plasmids. Relative luciferase activity was determined. *, P < 0.05, significant difference between values obtained for cells transfected with the p-3.62-LUC and control plasmids. D, effect of RhoA inhibition on p-3.62-LUC activity in the absence of syndecan-2. U2OS cells were cotransfected with control or pRhoN19 expression plasmids, control, or syndecan-2-specific siRNA and p-3.62-LUC. *, P < 0.05, significant difference with values obtained at basal conditions. greatly increased basal syndecan-2 expression. These results strongly suggest that, in addition to continuous activation of the Wnt/β-catenin/TCF pathway, syndecan-2 repression may depend on other Wnt-dependent mediators. One of the important Wnt signaling mediators, the small GTPase RhoA, was shown to play an oncogenic role in osteosarcoma. Notably, RhoA/JNK plays a negative role in drug-induced apoptosis and drug resistance in bone tumors. RhoA expression was found to be increased in the poor responder group of patients with high-grade osteosarcoma (19, 32, 33) . Here, we show that RhoA mediates part of the Wnt-dependent repression of syndecan-2 because expression of constitutively activated RhoA reduced the positive effect of sFRP-1 on syndecan-2 expression. Interestingly, in contrast to exogenous Wnt3a, pRhoA activation and exogenous Wnt5a displayed no or very little effect on the basal syndecan-2 transcription, whereas pRhoA dominant negative strongly enhanced it. These results may suggest that the Wnt/RhoA signal cannot be further activated in these cells. In support of this conclusion, previous studies have shown that RhoA signaling is high in U2OS cells and that osteosarcoma cells spontaneously produce high levels of Wnt5a (4, 34, 35) . Hence, endogenous factors such as Wnt5a may blunt exogenous RhoA activation. We report that Wnt/RhoA signaling regulates syndecan-2 ectodomain shedding in U2OS cells. A RhoA-dependent release of syndecan-2 could be mediated by matrix metalloproteinases (MMP) that are involved in syndecan shedding (23) . Indeed, RhoA was previously found to regulate MMP-2 in osteosarcoma cells (36) and we found higher levels of shed syndecan-2 in the medium conditioned by the osteosarcoma cells than the osteoblastic cells. Regulation of syndecan-2 level through protein shedding may play a key role in cancer cells because the functions of membraneanchored syndecans are clearly distinct from those of released ectodomain. This is exemplified by the specific role of shed syndecan-2 during angiogenic processes (37) . Because all functions of syndecan-2 have been shown to depend on the extracellular glycosaminoglycan chains that bind ligands and only full-membrane syndecan-2 can signal in response to the cell environment, shedding of the ectodomain should result in an inhibition of syndecan-2 signaling.
Self-induction of syndecan-2 is consistent with previous data showing that apoptotic factors induce syndecan-2, whereas syndecan-2 drives the apoptotic response (8, 12) . Hence, on apoptotic stimulation, syndecan-2 expression may rapidly increase to adapt the normal cell response. This strengthens the idea that syndecan-2 is an inducible gene and that not only basal expression but also its induction may be altered in osteosarcoma cells. Our results indicate that syndecan-2 controls the positive regulation loop through activation of p190RhoGAP and inhibition of RhoA activation in murine osteoblastic cells and U2OS cells. This action of syndecan-2 on RhoA activity is consistent with the opposite role of syndecan-2 and RhoA in osteosarcoma cells. Indeed, syndecan-2 was shown to suppress MMP activation, favor adhesion, and prevent migration in some cancer cells (12, 38) , whereas RhoA activity is associated with reduced cell spreading and polarity and increased osteosarcoma cell motility. Through ROR2/RhoA/JNK signaling, Wnt5a also regulates osteosarcoma cell invasiveness (20, 35) .
In conclusion, the present results reveal a molecular network controlling syndecan-2 expression in osteosarcoma cell lines (Fig. 6C) . The canonical Wnt/β-catenin pathway represses syndecan-2 transcription. RhoA also plays a large part in Wnt-dependent syndecan-2 inhibition, in part, by controlling syndecan-2 shedding. Syndecan-2 can activate its own transcription by downregulation of RhoA. Thus, the Wnt/β-catenin/TCF pathway was found to contribute to low basal syndecan-2 transcription. This favors high Wnt/RhoA signaling, which, in turn, may contribute to the further reduction of syndecan-2 protein levels, breaking the amplification loop. These results identify syndecan-2 as a Wnt target and bring new insights into the pathologic role of Wnt factors in osteosarcoma.
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